Contact the Desk

Editorial correspondence

Notes on the record itself are the most useful messages this desk receives: a citation that's been superseded by newer data, a trial that has posted results not yet reflected here, an approval status that has changed, or a peer-reviewed source on semaglutide, tirzepatide, or tesamorelin that belongs on the references page. The most actionable messages name three things — which page, the specific passage, and a DOI or PubMed identifier for the correction — so the claim can be checked against its source before anything changes.

This mailbox is read by the person maintaining the site, not a support queue or a triage team, so a specific, sourced note gets read faster than a general question. If a claim on any page reads as overstated relative to its citation, that is also worth flagging — the whole point of the citation trail is that it can be checked, and being told when it doesn't hold up is how it stays accurate.

Editorial mailbox: editors@mypeptidesrx.com

What this desk can't help with

Because this site reports the literature rather than practicing medicine, a few kinds of requests fall outside what it can do: weighing in on or endorsing use of any peptide discussed here; naming a dose, schedule, or route for a specific person; judging whether a cited finding applies to an individual's situation; or pointing toward a supplier, vendor, or sourcing option for any compound. Semaglutide, tirzepatide, and tesamorelin are all prescription medicines — access runs through a licensed prescriber, not through this site. Anyone with a medical question should take it to a clinician who can review their actual history; replies to this mailbox aren't guaranteed and may be slow.